Sun Pharma Advanced Research Company Limited

Total Valuation

Sun Pharma Advanced Research Company Limited carries a market capitalization of 84.99B, placing it among publicly traded companies globally. Its enterprise value stands at 42.73B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Sun Pharma Advanced Research Company Limited currently has 324.52M shares outstanding.

Valuation Ratios

Sun Pharma Advanced Research Company Limited trades at a trailing price-to-earnings ratio of 2.39. The price-to-sales ratio is 1.98, and the price-to-book ratio stands at 114.53.

Enterprise Valuation

On an enterprise value basis, Sun Pharma Advanced Research Company Limited trades at an EV/EBITDA multiple of 2.69 and an EV/FCF ratio of 125.18. The EV/Sales ratio of 2.27 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 2.69 provides insight into valuation relative to core operating earnings.

Financial Position

Sun Pharma Advanced Research Company Limited maintains a current ratio of 2.47, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 41.78, indicating elevated leverage, while an interest coverage ratio of 46.54 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Taxes

Stock Price Statistics

Sun Pharma Advanced Research Company Limited's stock has gained approximately 66.49698% over the past 52 weeks. The 50-day moving average sits at 199.57, while the 200-day moving average is 149.61.

Income Statement

Over the trailing twelve months, Sun Pharma Advanced Research Company Limited generated 18.79B in revenue and converted that into 15.53B in net income, yielding earnings per share of 47.90. EBITDA reached 15.89B, while operating income came in at 15.89B.

Balance Sheet

Sun Pharma Advanced Research Company Limited holds 26.20M in cash and equivalents against 5.59B in total debt, resulting in a net debt position of 5.55B. Total book value stands at 324.50M, with working capital of 11.08B providing operational flexibility.

Margins

Sun Pharma Advanced Research Company Limited operates with a gross margin of 97.54, reflecting its pricing power and cost economics. The operating margin of 84.53 and net profit margin of 82.65 provide insight into operational efficiency.

Scores

Sun Pharma Advanced Research Company Limited posts an Altman Z-Score of 6.71, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.